As part of our integrated Pharmaceutical Development & Manufacturing platform, we provide comprehensive Biosimilar Development solutions . Our expertise in coagulation factor VIII (FVIII) and factor IX (FIX) biosimilars enables precise molecular design and development strategies that align with advanced regulatory and scientific standards.
Overview of Coagulation Factor VIII/IX Biosimilar Development
Coagulation factors VIII and IX are essential glycoproteins that serve as key mediators in the coagulation cascade, responsible for maintaining hemostatic balance. Recombinant biosimilars of FVIII and FIX have become critical components in biopharmaceutical innovation due to their structural complexity and therapeutic significance. In coagulation factor VIII/IX biosimilar development, establishing physicochemical and functional comparability with reference products requires advanced analytical and bioengineering platforms. This process encompasses host cell optimization, bioassay design, and manufacturing process development under stringent quality attributes.
Our Services
We offer end-to-end services for coagulation factor VIII/IX biosimilar development under our pharmaceutical development & manufacturing platform. Our services encompass analytical characterization, process development, formulation optimization, and stability assessment—all tailored to meet biosimilar-specific regulatory and scientific expectations.
Analytical Characterization Service
We provide comprehensive analytical characterization services to establish structural and functional comparability with reference coagulation factors. Our analyses include primary structure verification, glycosylation mapping, disulfide bond profiling, and higher-order structure assessment using advanced mass spectrometry, chromatography, and biophysical techniques. Functional comparability is confirmed through enzymatic activity and binding assays to ensure biological equivalence.
Upstream Cell Line and Process Development Service
Our upstream development team designs robust cell line platforms optimized for FVIII and FIX expression in mammalian systems. We evaluate multiple host cell systems, vector constructs, and signal peptides to enhance protein yield and post-translational fidelity. Parallel bioreactor scale studies are conducted to optimize parameters such as culture conditions, feeding strategies, and productivity profiles, ensuring reproducibility and scalability of the biosimilar production process.
Downstream Purification and Process Optimization Service
Purification of FVIII and FIX biosimilars requires multi-step chromatographic processes designed to preserve protein conformation and remove process-related impurities. We design and validate purification workflows combining affinity, ion exchange, and size-exclusion chromatography tailored for high recovery and purity. Process optimization ensures scalability and robustness while maintaining alignment with biosimilarity criteria.
Formulation and Stability Development Service
Our formulation scientists develop stable liquid or lyophilized formulations that maintain molecular integrity and biological activity during storage. We assess excipient compatibility, pH stability, and buffer conditions to prevent aggregation or degradation. Accelerated and real-time stability studies under ICH guidelines are performed to confirm product consistency throughout shelf life and transport.
Comparability and Analytical Similarity Assessment Service
A critical stage in biosimilar development, our comparability service integrates analytical, functional, and biophysical data to establish high similarity to the originator molecule. Our comprehensive comparability reports include molecular fingerprinting, potency analysis, and product-specific impurity profiling to ensure compliance with international biosimilar regulatory frameworks.
Through our specialized expertise and integrated CDMO capabilities, we deliver end-to-end support for coagulation factor VIII/IX biosimilar development—from analytical characterization to process design and formulation. We welcome inquiries from partners seeking scientifically rigorous and compliant biosimilar development solutions.
Our products and services are for research use only.
